Listing 3.11 Lung Transplantation in 2026: Why Lung Transplant Recipients Get 3 Years of Automatic Disability Rather Than 1, How Chronic Lung Allograft Dysfunction and Bronchiolitis Obliterans Syndrome Extend the Window Past 36 Months, and What the CDR Actually Reviews

By Anthony Albert, Benefits Research Director. Published July 24, 2026.

A lung transplant gets you 3 years of automatic disability. Not 1 year, not 12 months. Three full years from the date of surgery. That is longer than any other transplant listing in the SSA Blue Book. A heart transplant gets 1 year under 4.09. A liver transplant gets 1 year under 5.09. A kidney transplant gets 1 year under 6.04. A bone marrow or stem cell transplant gets 12 months under 7.17. Only lung transplant gets 3 years, and there is a reason for that.

Lung transplantation has the worst long-term survival of any solid organ transplant. Median survival is around 6.5 years for double lung and 4.5 years for single lung, per ISHLT registry data. Five-year survival is under 60 percent. That is not because surgeons are worse or patients are sicker at baseline. It is because the transplanted lung is exposed to inhaled particulates, pathogens, and antigens with every breath, and chronic lung allograft dysfunction (CLAD) develops in roughly 50 percent of survivors by 5 years.

SSA recognized this reality in the current 3.00 respiratory rules. The 3 year automatic window under 3.11 reflects the reality that lung transplant recovery is not measured in months, and that complications frequently emerge in the second and third year, not just the first.

This article covers the exact 3.11 text, how the 3 year window works, what happens at the CDR, common complications that extend disability past 36 months, indications for lung transplant, pediatric 103.11, and the Lung Allocation Score (LAS) that governs pre-transplant priority. Four worked cases at the end.

The Listing 3.11 Text

Section 3.00M explains the rule. If you receive a lung transplant, or a lung transplant simultaneously with other organs such as the heart, you are considered disabled under 3.11 for 3 years from the transplant date. After that, SSA evaluates residual impairment based on:

• Adequacy of post-transplant function
• Frequency and severity of any rejection episodes
• Complications in other body systems
• Adverse treatment effects

The 3 year rule is unconditional. No functional testing during the window. No pulmonary function tests required. Just the transplant date and the fact of transplantation.

Why 3 Years and Not 1

Three clinical realities drive the 3 year window:

Primary graft dysfunction in the first days

Primary graft dysfunction (PGD) affects 15 to 30 percent of lung transplant recipients in the first 72 hours. It ranges from mild oxygenation impairment (Grade 1: PaO2/FiO2 ratio over 300) to severe (Grade 3: ratio under 200). Grade 3 PGD carries 30-day mortality of 20 to 40 percent and increases risk of CLAD. Survivors face weeks to months of ICU care and rehabilitation.

Acute rejection in months 1 through 12

Acute cellular rejection occurs in 30 to 55 percent of lung transplant recipients within the first year. It is diagnosed by transbronchial biopsy with ISHLT Grade A grading (A0 no rejection, A1 minimal, A2 mild, A3 moderate, A4 severe). Antibody-mediated rejection (AMR) occurs in 5 to 15 percent and is more difficult to treat. Multiple acute rejection episodes are the strongest predictor of chronic rejection.

Chronic lung allograft dysfunction in years 2 through 5

CLAD is the leading cause of death after year 1 in lung transplant recipients. Two main phenotypes:

• Bronchiolitis Obliterans Syndrome (BOS): obstructive pattern with sustained decline in FEV1 to 80 percent or less of best post-transplant baseline. Fibrotic obliteration of small airways. Most common CLAD phenotype (60 to 75 percent).
• Restrictive Allograft Syndrome (RAS): restrictive pattern with sustained decline in TLC to 90 percent or less of baseline, plus parenchymal opacities on imaging. Worse prognosis than BOS.
• Mixed phenotype: features of both.

Median time from transplant to CLAD onset is 3 to 5 years, but 15 to 25 percent develop CLAD in years 1 to 3. That is a major reason the SSA window extends to 3 years. Many recipients are functionally recovered at year 1 but decline in years 2 and 3.

Indications for Lung Transplant That Route Through 3.11

Lung transplantation is indicated for end-stage lung disease with expected survival under 2 years without transplant. Common indications:

Chronic obstructive pulmonary disease (COPD)

The most common indication overall (30 to 35 percent of adult lung transplants). Includes emphysema and chronic bronchitis. Alpha-1 antitrypsin deficiency (AATD) is a subset with earlier onset. Referral thresholds include BODE index 7 to 10, FEV1 under 25 percent predicted, resting hypoxemia, or hypercapnia. Pre-transplant patients typically meet Listing 3.02 (Chronic Respiratory Disorders) on FEV1, FVC, DLCO, ABG, or SpO2 criteria.

Interstitial lung disease (ILD)

Second most common indication (30 to 35 percent). Includes idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), hypersensitivity pneumonitis (HP), sarcoidosis with progressive fibrosis, connective tissue disease-associated ILD, and drug-induced ILD. Rapid progression drives urgent transplant listing. Pre-transplant patients typically meet 3.02 on DLCO or ABG criteria.

Pulmonary arterial hypertension (PAH)

10 to 15 percent of lung transplants. Includes idiopathic PAH, heritable PAH (BMPR2, ALK1, ACVRL1 mutations), connective tissue disease-associated PAH, congenital heart disease-associated PAH, and drug-induced PAH. Pre-transplant patients meet Listing 3.09 (Chronic Pulmonary Hypertension, mean pulmonary artery pressure 40 mm Hg or more).

Cystic fibrosis and other suppurative diseases

10 to 15 percent of lung transplants. Bilateral lung transplant is standard for CF due to bilateral infection. Pre-transplant patients meet Listing 3.04 (Cystic Fibrosis) on FEV1, hospitalization, pneumothorax, hemoptysis, or respiratory failure criteria. Bronchiectasis (Listing 3.07) also included.

Retransplantation

3 to 5 percent of lung transplants. Retransplant for graft failure, CLAD, or acute rejection refractory to treatment. Outcomes worse than first transplant. The 3.11 clock resets to the retransplantation date.

Lung Allocation Score (LAS)

Lung allocation in the US is based on the Lung Allocation Score, which balances medical urgency against post-transplant survival benefit. Score range 0 to 100. Calculated from 12 to 15 clinical variables including diagnosis category, FVC, PAP, oxygen requirement, six minute walk distance, functional status, creatinine, BMI, diabetes, mechanical ventilation, and ECMO. Higher LAS means higher priority.

• LAS under 40: standard priority, longer wait times
• LAS 40 to 60: elevated urgency
• LAS 60 to 80: high urgency, typically ambulatory but severely limited
• LAS 80 to 100: extreme urgency, often on ECMO or mechanical ventilation

In March 2023, the LAS was replaced by the Continuous Distribution framework, which uses a composite Lung Allocation Score plus geographic proximity weighting. The clinical variables are similar but the mathematical framework differs.

Pre-Transplant Onset Under 3.02, 3.04, 3.07, 3.09, and 3.14

Most lung transplant patients meet a respiratory listing well before transplant. Common pre-transplant paths:

3.02 Chronic Respiratory Disorders

Five paragraphs (A-C) with FEV1, FVC, DLCO, ABG, and SpO2 thresholds. FEV1 tables under 3.00E vary by sex and height (typically 1.05 to 1.85 L for men, 0.80 to 1.55 L for women). DLCO under 10.5 mL/min/mmHg meets 3.02C1. ABG PaO2 below 60 (sea level) meets 3.02C2. SpO2 87 percent or below meets 3.02C3.

3.04 Cystic Fibrosis

FEV1 table by sex and height under 3.04A, three hospitalizations of 48 hours each under 3.04B, or pneumothorax/hemoptysis/respiratory failure events under 3.04C, D, E.

3.07 Bronchiectasis

Three hospitalizations of 48 hours each within a 12 month period, 30 days apart.

3.09 Chronic Pulmonary Hypertension

Mean pulmonary artery pressure 40 mm Hg or more on right heart catheterization while medically stable.

3.14 Respiratory Failure

Invasive mechanical ventilation or noninvasive ventilation (BiPAP) at least 48 hours twice within a 12 month period, 30 days apart. Common in ILD, muscular dystrophy, and end-stage COPD.

Meeting one of these listings in the pre-transplant period sets the disability onset date months or years before the surgery, opening retroactive benefits.

What Happens at the 36 Month CDR

Under POMS DI 28010.030, Listing 3.11 is a listing with a specified timeframe and triggers CDR at 36 to 42 months. SSA reviews residual impairment under the 3.00M factors:

Post-transplant lung function

Pulmonary function tests (spirometry, lung volumes, DLCO) at 12, 24, and 36 months. Best post-transplant baseline is typically the highest FEV1 in months 3 to 6. Sustained decline to 80 percent or less of baseline defines BOS. Sustained decline in TLC to 90 percent or less with parenchymal opacities defines RAS. Six minute walk distance and desaturation.

Rejection frequency and severity

ISHLT Grade A biopsies over the 36 months, treatment history, and any AMR episodes. Recurrent A2 or higher rejection strongly predicts CLAD.

Complications in other body systems

Calcineurin inhibitor nephrotoxicity (evaluate under 6.03, 6.04, or 6.05). New-onset diabetes after transplant (Section 9 endocrine referrals). Osteoporosis with fractures (1.19). PTLD or other secondary malignancies (13.00). Cardiovascular disease from chronic steroids (4.02). Neurologic complications (11.00). Hepatobiliary complications (5.05).

Adverse treatment effects

Immunosuppression toxicity is nearly universal at 3 years. Tacrolimus tremor, hypertension, hyperlipidemia, neurotoxicity. Prednisone effects (osteoporosis, diabetes, cataracts). Mycophenolate GI effects. mTOR inhibitor pneumonitis (rarely used in lung transplant due to airway healing concerns).

Extending Disability Past 36 Months

Most lung transplant recipients continue to qualify past 36 months due to CLAD or complications. Common paths:

CLAD (BOS or RAS) meets 3.02

Sustained decline in FEV1 to 80 percent of baseline typically pushes the recipient into 3.02 range within 1 to 2 years of CLAD onset. FEV1 under 1.05 to 1.85 L (varies by sex and height) meets 3.02A. Meanwhile RAS meets 3.02B on FVC.

Chronic hypoxemia meets 3.02C

Resting hypoxemia with SpO2 87 percent or lower meets 3.02C3. Ambulatory oxygen requirement supports RFC limitations even without meeting 3.02.

Repeated infection hospitalizations meet 3.07-equivalent path

Post-transplant recipients face high rates of CMV, pseudomonas, aspergillus, PJP, and other infections. Three hospitalizations of 48 hours each within 12 months meets the pattern used in 3.07 bronchiectasis and 3.03 asthma.

Respiratory failure with mechanical ventilation meets 3.14

Late-stage CLAD often requires BiPAP or continuous oxygen. If mechanical ventilation or BiPAP for 48 hours or more occurs twice in 12 months with 30 day spacing, 3.14 is met.

Retransplantation resets 3.11

Approximately 3 to 5 percent of lung transplant recipients undergo retransplantation for CLAD or acute graft failure. The 3.11 clock resets to the new transplant date.

Pediatric Listing 103.11

Pediatric lung transplant recipients qualify under Listing 103.11 with identical language: 3 years from transplant date, then residual impairment evaluation. Pediatric indications include cystic fibrosis, pulmonary hypertension, ILD, surfactant protein deficiency (SP-B, SP-C, ABCA3), pulmonary vein stenosis, and bronchopulmonary dysplasia post-prematurity. Pediatric lung transplant volumes are low (roughly 30 to 50 per year in the US), concentrated at St. Louis Children's, Texas Children's, Toronto SickKids, and a few other pediatric centers.

Documentation Checklist

1. Pre-transplant medical records including diagnosis, PFTs over time (FEV1, FVC, DLCO), ABGs, six minute walk tests, echocardiography, right heart catheterization if PH, and imaging
2. LAS calculation history from the transplant center
3. Transplant listing date and any status changes (ECMO, mechanical ventilation)
4. Transplant operative note with the exact date of transplantation and single vs double lung documentation
5. Transplant discharge summary and any PGD documentation
6. Post-transplant PFT series at 1, 3, 6, 12, 24, and 36 months
7. Transbronchial biopsies with ISHLT Grade A and B (airway) grading
8. Bronchoalveolar lavage results
9. Immunosuppression medication list (typically tacrolimus + mycophenolate + prednisone)
10. Infection episode records (CMV PCR viral loads, aspergillus galactomannan, pseudomonas cultures, PJP diagnosis)
11. CLAD diagnosis and phenotype (BOS vs RAS vs mixed)
12. Complications: creatinine and eGFR trend, HbA1c for NODAT, DEXA for osteoporosis, cardiac imaging
13. Treating transplant pulmonologist narrative statement or RFC

Four Worked Cases

Case One, Sarah, 62, Pennsylvania

Sarah has IPF diagnosed 4 years ago with rapid decline. Pre-transplant FVC 42 percent predicted, DLCO 24 percent, resting SpO2 88 percent, six minute walk distance 220 meters with desaturation to 82 percent. She met Listing 3.02C1 (DLCO under 10.5) 18 months before transplant. Received bilateral lung transplant on March 8, 2026. She filed for SSDI in November 2024 during her pre-transplant workup. Disability onset established at October 15, 2024 based on DLCO of 8.9 documented that month. Automatic disability through March 7, 2029. CDR scheduled at 36 to 42 months.

Case Two, Marcus, 55, California

Marcus has alpha-1 antitrypsin deficiency (Pi ZZ genotype) with emphysema. Pre-transplant FEV1 21 percent predicted, hypercapnia with PCO2 55, oxygen dependent 4 L continuous. Met 3.02A on FEV1 threshold 2 years before transplant. Received single lung transplant on August 15, 2024. Uncomplicated post-op. At 18 months, acute cellular rejection A3 on surveillance biopsy, treated with steroid pulse. At 30 months, FEV1 declined from post-transplant peak of 68 percent to 48 percent, meeting BOS criteria. At 36 month CDR (August 2027), BOS with FEV1 in 3.02A range plus recurrent CMV pneumonitis meets 3.02 and infection-hospitalization pattern. SSDI continues.

Case Three, Emma, 8, Missouri

Emma has cystic fibrosis (F508del homozygous). Received bilateral lung transplant at age 6 in April 2024. Post-op complicated by CMV enteritis and one episode of A2 rejection at 4 months. Recovered well. At age 8 (24 months post-transplant), lung function at 92 percent of predicted, growth catching up, tolerating tacrolimus. At 36 month CDR (April 2027), functional recovery apparent. SSI benefits terminate under residual evaluation. If CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor) is needed for CF pancreatic complications, evaluate under 5.08 or Section 9 endocrine.

Case Four, Robert, 58, Georgia

Robert has idiopathic PAH with mean PAP 62 mm Hg despite triple therapy (macitentan + tadalafil + treprostinil IV). LAS 68. Received bilateral lung transplant on January 12, 2024. Post-op complicated by Grade 3 PGD requiring ECMO for 8 days. Prolonged ICU stay 6 weeks. Rehabilitation 4 months. At 12 months, acute cellular rejection A2 treated with steroid pulse. At 30 months, RAS diagnosed with FVC declining from 78 to 62 percent of predicted plus parenchymal opacities on HRCT. At 36 month CDR (January 2027), RAS meets 3.02B on FVC threshold plus recurrent aspergillus infection meets infection pattern. SSDI continues under 3.02 residual evaluation.

Denial Counters

Denial reason: 12 months not yet elapsed from transplant

3.11 does not require 12 months to elapse before filing. The 3 year rule applies from the transplant date. File as soon as possible after surgery or even before if the transplant is scheduled.

Denial reason: DDS wants pulmonary function testing during the 3 year window

The 3.11 rule is unconditional. No PFTs required during the window. Cite 3.00M explicitly and attach the operative note.

Denial reason: only 3 years automatic, not more

The 3 year rule is a minimum. After 36 months, SSA evaluates residual impairment under 3.00M. Most recipients continue to qualify through CLAD, chronic hypoxemia, recurrent infections, respiratory failure, or complications in other body systems. Submit updated PFTs, biopsies, infection records, and complication documentation at the CDR.

Denial reason: CDR terminates at 36 months despite CLAD

Appeal within 60 days. Elect to continue benefits during appeal (10 day rule). Submit CLAD-specific evidence: PFT series showing sustained FEV1 or FVC decline to CLAD thresholds, transbronchial biopsies, imaging showing airway or parenchymal changes. Argue continued qualification under 3.02 (chronic respiratory disorders) directly.

State Considerations

Lung transplant centers concentrate in academic medical centers. Highest volume US centers include hospitals in Pennsylvania (UPMC, Penn), North Carolina (Duke), Washington (University of Washington), California (Stanford, UCLA, UCSF), Florida (Mayo Jacksonville), Texas (Houston Methodist, Baylor), Ohio (Cleveland Clinic, University Hospitals), Minnesota (University of Minnesota), and Missouri (Barnes Jewish, St. Louis Children's for pediatric).

Pediatric lung transplant is highly concentrated. Only 4 to 6 US centers do meaningful pediatric volume: St. Louis Children's, Texas Children's, Duke, Toronto SickKids, and a few others.

Regional LAS variability affects wait times and pre-transplant disability duration. UNOS Region 8 (Colorado, Kansas, Nebraska, Wyoming, Iowa, Missouri) historically has shorter wait times than Region 5 (California, Arizona, Nevada, New Mexico, Utah). Longer regional wait times mean longer pre-transplant disability periods with continued qualification under 3.02, 3.04, 3.07, 3.09, or 3.14.

Related Blue Book Reading

• Listing 3.02 Chronic Respiratory Disorders
• Listing 3.04 Cystic Fibrosis
• Listing 3.07 Bronchiectasis
• Listing 3.09 Chronic Pulmonary Hypertension
• Listing 3.14 Respiratory Failure
• Listing 5.09 Liver Transplantation
• Listing 7.17 Bone Marrow or Stem Cell Transplantation

Frequently Asked Questions